Reference
Thompson G, et al. The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK. 50th Annual Meeting of the European Association for the Study of Diabetes : abstr. 817, 15 Sep 2014. Available from: URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3556&sKey=989e4b53-a24f-4d80-b582-2df4d2907d67&cKey=7ff5fc56-9693-417b-a8f3-17a857dc4697&mKey=a1c98495-3d5b-461a-ab97-eeb119269c55
Rights and permissions
About this article
Cite this article
Canagliflozin cost effective for T2DM in UK. PharmacoEcon Outcomes News 715, 12 (2014). https://doi.org/10.1007/s40274-014-1670-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1670-9